Home › Research › Prevention and risk
Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial
ASPREE Investigator Group.. Contemporary clinical trials, 2013-10-07
Topic: Risk, prevention and care in population studies
Plain-language summary
Cost-effective strategies to maintain healthy active lifestyle in aging populations are required to address the global burden of age-related diseases. ASPREE will examine whether the potential primary prevention benefits of low dose aspirin outweigh the risks in older healthy individuals. Our primary hypothesis is that daily oral 100 mg enteric-coated aspirin will extend a composite primary endpoint termed 'disability-free life' including onset of dementia, total mortality, or persistent disability in at least one of the Katz Activities of Daily Living in 19,000 healthy participants aged 65 years and above ('US minorities') and 70 years and above (non-'US minorities'). ASPREE is a double-blind, randomized, placebo-controlled trial of oral 100mg enteric-coated acetyl salicylic acid (ASA) or matching placebo being conducted in Australian and US community settings on individuals free of dementia, disability and cardiovascular disease (CVD) events. Secondary endpoints are all-cause and cause specific mortality, fatal and non-fatal cardiovascular events, fatal and non-fatal cancer (excluding non-melanoma skin cancer), dementia, mild cognitive impairment, depression, physical disability, and clinically significant bleeding. To 20 September 2013 14,383 participants have been recruited. Recruitment and study completion are anticipated in July 2014 and December 2018 respectively. In contrast to other aspirin trials that have largely focused on cardiovascular endpoints, ASPREE has a unique composite primary endpoint to better capture the overall risk and benefit of aspirin to extend healthy independent lifespan in older adults in the US and Australia.
What this study adds
Evidence grade: High
This is a trial of 14,383 participants. ASPREE is a randomized, placebo-controlled trial testing whether daily low-dose aspirin extends 'disability-free life', a composite that includes onset of dementia, in healthy older adults. This paper reports the study design only, so no results on whether aspirin prevents dementia are available here.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
ASPREE Investigator Group. (2013). Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial. Contemporary clinical trials. https://doi.org/10.1016/j.cct.2013.09.014
Vancouver
ASPREE Investigator Group. Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial. Contemporary clinical trials. 2013. doi:10.1016/j.cct.2013.09.014. PMID: 24113028.
BibTeX
@article{study2013-24113028,
author = {{ASPREE Investigator Group}},
title = {{Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial}},
journal = {Contemporary clinical trials},
year = {2013},
doi = {10.1016/j.cct.2013.09.014},
pmid = {24113028},
url = {https://doi.org/10.1016/j.cct.2013.09.014}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Secondary endpoints are all-cause and cause specific mortality, fatal and non-fatal cardiovascular events, fatal and non-fatal cancer (excluding non-melanoma skin cancer), dementia, mild cognitive impairment, depression, physical disability, and clinically significant bleeding.
- In contrast to other aspirin trials that have largely focused on cardiovascular endpoints, ASPREE has a unique composite primary endpoint to better capture the overall risk and benefit of aspirin to extend healthy independent lifespan in older adults in the US and Australia.
Why it matters
ASPREE is a randomized, placebo-controlled trial testing whether daily low-dose aspirin extends 'disability-free life', a composite that includes onset of dementia, in healthy older adults. This paper reports the study design only, so no results on whether aspirin prevents dementia are available here.
New to this subject? Start with our plain-English guide: Prevention →
Study details
- Participants14,383
- Evidence strengthHigh
How this study scored 70/100
Published in a peer-reviewed journal, and it is a randomized controlled trial. Scored zero for effect reported because the record does not state it. We have no data on senior author's track record and institution's track record, so those were left out: it earned 65 of the 93 points we could judge it on, which is 70 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Contemporary clinical trials) |
| Journal's citation record | 1 / 4 | Contemporary Clinical Trials: journal h-index 93 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2013 — within 20 year(s) of the newest study here |
| Sample size | 4 / 4 | 14,383 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 2 / 2 | Randomized and blinded or placebo-controlled (as stated in the record) |
| Times cited | 6 / 7 | Cited 310 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 20.7 citations a year over 15 year(s) since 2013 |
| Impact for its field and year | 3 / 6 | Cited 7.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 10 other studies in this library |
| Still being cited | 3 / 4 | Cited 98 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 24113028) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 65 / 93 | Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 65 of the 93 points we could judge it on is 70 out of 100. |
| Total | 70 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
10 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Prevention and risk from nearby years
Also tagged “palliative”
858 studies in the library carry the topic tag “palliative”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 858 tagged studies.